1260665-60-8

Basic information

• Product Name: 3-bromo-1,6-naphthyridin-5(6H)-one
• Synonyms: 3-bromo-1,6-naphthyridin-5(6H)-one;3-bromo-5,6-dihydro-1,6-naphthyridin-5-one
• CAS NO: 1260665-60-8
• Molecular Formula: C8H5BrN2O
• Molecular Weight: 225.0421
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 1260665-60-8.mol

Chemical Properties

• Boiling Point: 452.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.711±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.13±0.20(Predicted)
• CAS DataBase Reference: 3-bromo-1,6-naphthyridin-5(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-1,6-naphthyridin-5(6H)-one(1260665-60-8)
• EPA Substance Registry System: 3-bromo-1,6-naphthyridin-5(6H)-one(1260665-60-8)

Safety Data

• Hazardous Substances Data: 1260665-60-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-bromo-1,6-naphthyridin-5(6H)-one is used as a reagent for the synthesis of pharmaceutical compounds that contain a naphthyridin substructure. Its presence in these compounds can contribute to their biological activity and therapeutic potential, making it a crucial component in the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-bromo-1,6-naphthyridin-5(6H)-one serves as a key building block for designing and creating novel therapeutic agents. Its unique chemical properties allow for the development of drugs with improved efficacy, selectivity, and reduced side effects.
Used in Drug Discovery:
3-bromo-1,6-naphthyridin-5(6H)-one is utilized in drug discovery processes to identify and optimize potential drug candidates. Its incorporation into various chemical structures can lead to the discovery of new therapeutic agents with specific pharmacological properties, targeting a wide range of diseases and conditions.
Used in Research and Development:
3-bromo-1,6-naphthyridin-5(6H)-one is also employed in research and development settings, where it is used to study the structure-activity relationships of naphthyridin-containing compounds. Understanding these relationships can help researchers design more effective drugs and predict their potential therapeutic applications.

Upstream product

• 290-87-9 1,3,5-Triazine 
• 129477-21-0 ethyl 5-bromo-2-methyl-pyridine-3-carboxylate 

Downstream Products

• 1173699-31-4 AMG 337 
• 1393553-06-4 3-methoxy-1,6-naphthyridin-5(6H)-one 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust in Vivo Antitumor Activity

Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, we report the discovery of compound 23 (AMG 337), which demonstrates nanomolar inhibition of MET kinase activity, desirable preclinical pharmacokinetics, significant inhibition of MET phosphorylation in mice, and robust tumor growth inhibition in a MET-dependent mouse efficacy model.

Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461

Abstract Two series of novel 1,5-naphthyridine and 1,6-naphthyridine derivatives were designed and synthesized based on the c-Met kinase inhibitor MK-2461 under the guidance of scaffold hopping strategy. All were tested on c-Met kinase and in vitro anti-tumor activities against Hela and A549 cell lines. The results indicated that 1,6-naphthyridine was a more promising c-Met inhibitory structure core compared with 1,5-naphthyridine. Among them, 26b and 26c showed the best enzymic and cytotoxic activities. The western blot experiments implied that the cytotoxic activity of 26c might be partially through suppressing the phosphorylation of c-Met kinase.

METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES

Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(l-methyl4H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2- methoxyethoxy)- 1,6-naphthyridin-5(6H)-one, and precursors thereof.